New combination between 4-{ 3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy} benzamide and an nmda receptor antagonist, and pharmaceutical compositions containing it
Disclosed herein is a combination of 4-{ 3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy]benzamide, particularly in the form of an oxalate or hydrochloride and an NMDA glutamatergic receptor antagonist, particularly memantine and more particularly in the form of an hydrochloride, and the use therof in the treatment of cognitive disturbances associated with cerebral aging and with neurodegenerative disease, such as Alzheimer’s disease.